PURPOSE: To evaluate prognostic value of pretreatment and posttreatment 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography (FDG-PET) in advanced hypopharyngeal carcinoma treated by chemoradiotherapy. PROCEDURES: Thirty-one patients underwent a baseline FDG-PET and then FDG-PET was repeated 7 weeks after chemoradiotherapy. Primary tumor uptake of FDG, measured as the maximal standardized uptake value (SUV(max)), was analyzed in relation to local control and survival. RESULTS: Neither local control nor cause-specific survival were associated with pretreatment SUV(max). In contrast, patients with a high posttreatment SUV(max) had significantly poorer local control (P = 0.002), as well as poorer cause-specific survival (P = 0.0075), compared to those with a low posttreatment SUV(max). This prognostic significance of posttreatment SUV(max) remained when only a subset of patients showing local complete response to chemoradiotherapy was analyzed. CONCLUSIONS: Posttreatment FDG uptake represents an independent prognostic factor for hypopharyngeal carcinoma treated by chemoradiotherapy. Patients with a high posttreatment FDG uptake may benefit from adjuvant chemotherapy.
PURPOSE: To evaluate prognostic value of pretreatment and posttreatment 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography (FDG-PET) in advanced hypopharyngeal carcinoma treated by chemoradiotherapy. PROCEDURES: Thirty-one patients underwent a baseline FDG-PET and then FDG-PET was repeated 7 weeks after chemoradiotherapy. Primary tumor uptake of FDG, measured as the maximal standardized uptake value (SUV(max)), was analyzed in relation to local control and survival. RESULTS: Neither local control nor cause-specific survival were associated with pretreatment SUV(max). In contrast, patients with a high posttreatment SUV(max) had significantly poorer local control (P = 0.002), as well as poorer cause-specific survival (P = 0.0075), compared to those with a low posttreatment SUV(max). This prognostic significance of posttreatment SUV(max) remained when only a subset of patients showing local complete response to chemoradiotherapy was analyzed. CONCLUSIONS: Posttreatment FDG uptake represents an independent prognostic factor for hypopharyngeal carcinoma treated by chemoradiotherapy. Patients with a high posttreatment FDG uptake may benefit from adjuvant chemotherapy.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: David L Schwartz; Joseph Rajendran; Bevan Yueh; Marc D Coltrera; Michael Leblanc; Janet Eary; Kenneth Krohn Journal: Arch Otolaryngol Head Neck Surg Date: 2004-12
Authors: Sandro V Porceddu; Elizabeth Jarmolowski; Rodney J Hicks; Rob Ware; LeAnn Weih; Danny Rischin; June Corry; Lester J Peters Journal: Head Neck Date: 2005-03 Impact factor: 3.147
Authors: Min Yao; Pifu Luo; Henry T Hoffman; Kristi Chang; Michael M Graham; Yusuf Menda; Huaming Tan; John M Buatti Journal: Am J Clin Oncol Date: 2007-06 Impact factor: 2.339
Authors: Musaddiq J Awan; Pierre Lavertu; Chad Zender; Rod Rezaee; Nicole Fowler; Lilit Karapetyan; Michael Gibson; Jay Wasman; Peter Faulhaber; Mitchell Machtay; Min Yao Journal: Eur J Nucl Med Mol Imaging Date: 2017-01-14 Impact factor: 9.236